Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2293-2301

  Hardwick, Rhiannon N ^a   Fisher, Craig D ^a   Canet, Mark J ^a   Lake, April D ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CELLOBIOSE QUINONE OXIDOREDUCTASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; GLUTATHIONE TRANSFERASE A3; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSCRIPTION FACTOR;

ARTICLE; DISEASE COURSE; ENZYME SYNTHESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONALCOHOLIC FATTY LIVER; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATOSIS;

ADULT; ANTIOXIDANTS; DISEASE PROGRESSION; FATTY LIVER; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2;

EID: 78649549021     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035006     Document Type: Article

References (37)

1. Adams LA and Lindor KD (2007) Nonalcoholic fatty liver disease. Ann Epidemiol 17:863-869.
2. Aleksunes LM, Goedken M, and Manautou JE (2006a) Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J Gastroenterol 12:1937-1940.
3. Aleksunes LM and Manautou JE (2007) Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 35:459-473. (Pubitemid 46911886)
4. Aleksunes LM, Slitt AL, Maher JM, Dieter MZ, Knight TR, Goedken M, Cherrington NJ, Chan JY, Klaassen CD, and Manautou JE (2006b) Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. Cell Stress Chaperones 11:356-363.
5. Ali R and Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41:265-278.
6. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231.
7. Clapper ML and Szarka CE (1998). Glutathione S-transferases - biomarkers of cancer risk and chemopreventive response. Chem Biol Interact 111-112:377-388.
8. Codreanu SG, Zhang B, Sobecki SM, Billheimer DD, and Liebler DC (2009) Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal. Mol Cell Proteomics 8:670-680.
9. Coles BF and Kadlubar FF (2005) Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease. Methods Enzymol 401:9-42.
10. Czeczot H, Scibior D, Skrzycki M, and Podsiad M (2006) Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol 53:237-242.
11. Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, and Cherrington NJ (2008) Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82:959-964.
12. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
13. Hayes JD, Flanagan JU, and Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88.
14. Henderson CJ and Wolf CR (2005) Disruption of the glutathione transferase pi class genes. Methods Enzymol 401:116-135.
15. Higashi K, Hiai H, Higashi T, and Muramatsu M (2004) Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle. Cancer Lett 209:155-163.
16. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322.
17. Jaiswal AK (2000) Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 29:254-262.
18. Jaiswal AK (2004) Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36:1199-1207.
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
20. Lickteig AJ, Fisher CD, Augustine LM, and Cherrington NJ (2007) Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol 21:216-220.
21. Lin YS, Hung SC, Wei YH, and Tarng DC (2009) GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. J Am Soc Nephrol 20:405-415.
22. Lu SC (2009) Regulation of glutathione synthesis. Mol Aspects Med 30:42-59.
23. Manfredi S, Calvi D, del Fiandra M, Botto N, Biagini A, and Andreassi MG (2009) Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with type 2 diabetes mellitus. Pharmacogenomics 10:29-34.
24. Mannervik B and Jemth P (1999) Measurement of glutathione transferases, in Current Protocols in Toxicology, pp 6.4.1-6.4.10, John Wiley & Sons, New York.
25. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, and Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81.
26. Martin NJ, Collier AC, Bowen LD, Pritsos KL, Goodrich GG, Arger K, Cutter G, and Pritsos CA (2009) Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. Mutat Res 674:93-100.
27. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40:S17-S29.
28. Moffit JS, Aleksunes LM, Kardas MJ, Slitt AL, Klaassen CD, and Manautou JE (2007) Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen. Toxicology 230:197-206.
29. Nagata K, Suzuki H, and Sakaguchi S (2007) Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 32:453-468.
30. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, and Ishikawa T (2006) Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 21:437-457.
31. Nguyen T, Huang HC, and Pickett CB (2000) Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J Biol Chem 275:15466-15473.
32. Pastore A, Federici G, Bertini E, and Piemonte F (2003) Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 333:19-39. (Pubitemid 36694824)
33. Ross D and Siegel D (2004) NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382:115-144.
34. Sakai M and Muramatsu M (2007) Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. Biochem Biophys Res Commun 357:575-578.
35. Talalay P and Dinkova-Kostova AT (2004) Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol 382:355-364.
36. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, and van Bladeren PJ (1997) Interactions of α,β-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact 108:67-78.
37. Zhang DD (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38:769-789.